Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies
- 15 December 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (24), 7587-7596
- https://doi.org/10.1158/0008-5472.can-11-0821
Abstract
Genomic alterations of the epidermal growth factor receptor (EGFR) gene play a crucial role in pathogenesis of glioblastoma multiforme (GBM). By systematic analysis of GBM genomic data, we have identified and characterized a novel exon 27 deletion mutation occurring within the EGFR carboxyl-terminus domain (CTD), in addition to identifying additional examples of previously reported deletion mutations in this region. We show that the GBM-derived EGFR CTD deletion mutants are able to induce cellular transformation in vitro and in vivo in the absence of ligand and receptor autophosphorylation. Treatment with the EGFR-targeted monoclonal antibody, cetuximab, or the small molecule EGFR inhibitor, erlotinib, effectively impaired tumorigenicity of oncogenic EGFR CTD deletion mutants. Cetuximab in particular prolonged the survival of intracranially xenografted mice with oncogenic EGFR CTD deletion mutants, compared with untreated control mice. Therefore, we propose that erlotinib and, especially, cetuximab treatment may be a promising therapeutic strategy in GBM patients harboring EGFR CTD deletion mutants. Cancer Res; 71(24); 7587–96. ©2011 AACR.Other Versions
This publication has 50 references indexed in Scilit:
- EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanismOncogene, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- A survey of glioblastoma genomic amplifications and deletionsJournal of Neuro-Oncology, 2009
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaJournal of Neuro-Oncology, 2009
- Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane SegmentCell, 2009
- Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodiesBritish Journal of Cancer, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceNature, 2007
- Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant GliomaNeuron, 2007
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005